AMRX
Amneal Pharmaceuticals, Inc.
AMRX has the edge over NVO overall, supported by stronger fundamentals and stronger valuation.
NVO
Novo Nordisk A/S
NVO trails on the overall score without a compensating advantage in the available component scores.
AMRX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Under pressure | |
| Unavailable |
AMRX's revenue and profitability are currently healthy, but its cash flow is under pressure. There isn't enough data to rate its balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
AMRX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 13x | $5.39 | -75% |
| Forward | 19x | $21.70 | — |
| Current | 53x | $21.70 | — |
| Fair | 58x | $23.71 | +9.2% |
| Expensive | 616x | $253 | +1064% |
Historical ranges are pointers, not guarantees.
AMRX's PE is in its fair range at 53x. If earnings grow as analysts expect, today's price would be 19x next year's earnings, in its cheap range.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over AMRX in the historical PE scenario, which offers more potential upside but is not a forecast.
AMRX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
AMRX has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
AMRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.14 | +178% |
| Q3 2026 | $0.41 | +1950% |
| Q2 2026 | $0.48 | +4700% |
| Q1 2026 | $0.37 | +$0.41 |
| Q4 2025 | $0.22 | +$0.60 |
| Q3 2025 | $0.02 | +$0.87 |
| Q2 2025 | $0.01 | +$0.80 |
| Q1 2025 | -$0.04 | +$0.69 |
| Q4 2024 | -$0.38 | +$0.10 |
AMRX's earnings per share have fallen from their peak: $0.41 over the past year, against $0.61 in late 2020.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
AMRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $862.7M | +10% |
| Q2 2026 | $796.2M | +9.9% |
| Q1 2026 | $722.5M | +3.9% |
| Q4 2025 | $814.3M | +11% |
| Q3 2025 | $784.5M | +12% |
| Q2 2025 | $724.5M | +3.2% |
| Q1 2025 | $695.4M | +5.5% |
| Q4 2024 | $730.5M | +18% |
AMRX's revenue has grown year over year for 22 quarters in a row: $863M last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 11% | +2.1 points |
| Q2 2026 | 16% | +0.9 points |
| Q1 2026 | 20% | +5.2 points |
| Q4 2025 | 14% | +3.4 points |
| Q3 2025 | 9% | -3.7 points |
| Q2 2025 | 15% | +1.8 points |
| Q1 2025 | 14% | +16 points |
| Q4 2024 | 10% | +8.1 points |
AMRX's operating margin was 11% last quarter, up 2.1 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over AMRX on profitability, with a higher operating margin.
AMRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $66.5M | -37% |
| Q2 2026 | -$51.9M | -185% |
| Q1 2026 | -$34.9M | -$29.2M |
| Q4 2025 | $108.5M | +5.5% |
| Q3 2025 | $106.2M | -15% |
| Q2 2025 | $61M | +110% |
| Q1 2025 | -$5.8M | +$7.9M |
| Q4 2024 | $102.9M | -18% |
AMRX still generates free cash flow, though less than at its 2020 peak: $88M over the past year.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over AMRX on cash flow, with more consistent year-over-year improvement.
AMRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.3% | +7.6M shares |
| 1 year | +3.4% | +11M shares |
| 3 years | +117% | +181M shares |
| 5 years | +121% | +184M shares |
| Available history | +154% | +204M shares |
AMRX has 336M diluted shares, up 3.4% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over AMRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
AMRX Net Leverage
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
AMRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.8 | Neutral |
| Stochastic | 86.7 | Overbought |
AMRX's weekly RSI is 69 (neutral) and its Stochastic is 87 (overbought).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
AMRX PE vs Healthcare Sector
| Metric | AMRX | Sector median | Relative |
|---|---|---|---|
| PE | 53x | 26x | 105% above |
| PE % | 40 | 29 | 11 pts above |
AMRX is trading at 53x earnings, a 105% premium to the Healthcare sector's median of 26x.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over AMRX on valuation relative to its sector.
AMRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.4 | 6.6% above |
| 20 week MA | $18.8 | 15% above |
| 50 week MA | $15.5 | 40% above |
| 100 week MA | $12.1 | 79% above |
| 200 week MA | $8.62 | 152% above |
AMRX has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
AMRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.51 | $4.43 | -1.8% |
| 2021 | $4.43 | $5.07 | +14% |
| 2022 | $5.07 | $2.20 | -57% |
| 2023 | $2.20 | $6.07 | +176% |
| 2024 | $6.07 | $7.82 | +29% |
| 2025 | $7.82 | $13.0 | +66% |
| 2026 YTD | $13.0 | $21.7 | +68% |
AMRX has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.